ReproCELL Inc. (JP:4978)
:4978
Top Page
ReproCELL Inc.
(4978)
Select Model
Select Model
Rating:56Neutral
Price Target:
¥177.00
▲(23.78% Upside)
Action:ReiteratedDate:03/07/26
The score is anchored by strong balance-sheet flexibility and improving profitability, but it is held back by weak cash generation (negative free cash flow) and lack of operating profitability. Technically the stock is in a constructive uptrend, while the very high P/E meaningfully pressures the overall rating.
Positive Factors
Strong balance sheet (near-zero debt)
Near-zero debt and steadily growing equity provide durable financial flexibility, lowering solvency risk and enabling the company to fund R&D, platform development, or selective M&A without immediate reliance on external financing. This structural strength supports multi‑month investment plans.
Negative Factors
Weak cash generation / negative free cash flow
Persistently negative free cash flow constrains the company’s ability to self‑fund growth and R&D. Even with improving accounting earnings, the cash shortfall may force equity or debt financing, diluting capital returns or increasing fixed obligations over a multi‑month horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet (near-zero debt)
Near-zero debt and steadily growing equity provide durable financial flexibility, lowering solvency risk and enabling the company to fund R&D, platform development, or selective M&A without immediate reliance on external financing. This structural strength supports multi‑month investment plans.
Read all positive factors
ReproCELL Inc. (4978) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥17.31B
Dividend YieldN/A
Average Volume (3M)510.74K
Price to Earnings (P/E)120.8
Beta (1Y)0.57
Revenue Growth1.24%
EPS Growth-33.41%
CountryJP
Employees96
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.29
Shares Outstanding95,147,890
10 Day Avg. Volume504,660
30 Day Avg. Volume510,736
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)1.52
Price to Sales (P/S)4.58
P/FCF Ratio-169.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.7
Revenue Forecast (FY)¥3.53B
ReproCELL Inc. Business Overview & Revenue Model
Company Description
ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, ...
How the Company Makes Money
null...
ReproCELL Inc. Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
83
Very Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.83B | 2.98B | 2.43B | 2.95B | 2.23B | 1.29B |
| Gross Profit | 1.51B | 1.63B | 1.10B | 1.13B | 785.42M | 456.10M |
| EBITDA | -252.70M | -79.70M | -372.18M | -307.23M | -587.37M | -962.63M |
| Net Income | -125.81M | 103.25M | -31.41M | -305.31M | -575.10M | -812.57M |
Balance Sheet | ||||||
| Total Assets | 9.25B | 9.67B | 9.05B | 8.36B | 8.10B | 6.05B |
| Cash, Cash Equivalents and Short-Term Investments | 4.72B | 3.94B | 6.57B | 6.38B | 4.64B | 4.60B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 80.00M | 80.00M |
| Total Liabilities | 591.24M | 685.81M | 741.03M | 780.63M | 844.53M | 656.43M |
| Stockholders Equity | 8.66B | 8.98B | 8.31B | 7.58B | 7.25B | 5.38B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -80.40M | -182.89M | -290.92M | -289.65M | -708.73M |
| Operating Cash Flow | 0.00 | 6.29M | -11.45M | -140.53M | -246.24M | -648.88M |
| Investing Cash Flow | 0.00 | -796.00M | 404.42M | -1.09B | -2.14B | -1.42B |
| Financing Cash Flow | 0.00 | 680.11M | 544.05M | 482.87M | 2.38B | 4.41M |
ReproCELL Inc. Technical Analysis
Neutral
143.00
Price Trends
170.92
Positive
163.47
Positive
177.78
Negative
Market Momentum
0.33
Positive
48.74
Neutral
23.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4978, the sentiment is Neutral. The current price of 143 is below the 20-day moving average (MA) of 174.80, below the 50-day MA of 170.92, and below the 200-day MA of 177.78, indicating a neutral trend. The MACD of 0.33 indicates Positive momentum. The RSI at 48.74 is Neutral, neither overbought nor oversold. The STOCH value of 23.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4978.
ReproCELL Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥17.31B | 120.78 | ― | ― | 1.24% | -33.41% | |
52 Neutral | ¥137.39B | -8.84 | ― | 2.18% | -0.16% | -802.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥25.42B | -34.16 | ― | ― | -5.65% | -469.19% | |
50 Neutral | ¥51.57B | -13.30 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥11.66B | -8.14 | ― | ― | -42.49% | -2.37% | |
45 Neutral | ¥20.31B | -11.30 | ― | ― | ― | 11.34% |
* Healthcare Sector Average
JP:4978
ReproCELL Inc.
182.00
57.00
45.60%
JP:4593
Healios KK
382.00
158.00
70.54%
JP:4599
StemRIM Inc.
324.00
65.00
25.10%
JP:4974
Takara Bio Inc.
1,141.00
417.00
57.60%
JP:7774
Japan Tissue Engineering Co., Ltd.
626.00
222.00
54.95%
JP:7776
CellSeed Inc.
300.00
-247.00
-45.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.